West Financial Advisors LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

West Financial Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 65 shares of the company’s stock, valued at approximately $58,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Gunderson Capital Management Inc. lifted its position in Eli Lilly and Company by 1.0% in the third quarter. Gunderson Capital Management Inc. now owns 22,497 shares of the company’s stock valued at $19,931,000 after purchasing an additional 223 shares during the period. Daymark Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 1.4% during the 3rd quarter. Daymark Wealth Partners LLC now owns 11,720 shares of the company’s stock worth $10,383,000 after buying an additional 162 shares in the last quarter. Saxon Interests Inc. lifted its holdings in shares of Eli Lilly and Company by 31.0% in the 3rd quarter. Saxon Interests Inc. now owns 444 shares of the company’s stock valued at $393,000 after buying an additional 105 shares during the period. Tilia Fiduciary Partners Inc. lifted its holdings in shares of Eli Lilly and Company by 1.4% in the 3rd quarter. Tilia Fiduciary Partners Inc. now owns 1,052 shares of the company’s stock valued at $932,000 after buying an additional 15 shares during the period. Finally, Eagle Wealth Strategies LLC boosted its stake in shares of Eli Lilly and Company by 1.0% in the third quarter. Eagle Wealth Strategies LLC now owns 4,079 shares of the company’s stock valued at $3,614,000 after buying an additional 39 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Barclays increased their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Finally, Bank of America lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Stock Up 0.7 %

LLY opened at $919.91 on Thursday. The firm has a market cap of $874.29 billion, a P/E ratio of 135.48, a PEG ratio of 2.78 and a beta of 0.42. The business’s fifty day simple moving average is $904.41 and its 200 day simple moving average is $850.31. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.